1

G R A D U A T E S T U D E N T H A N D B O O K Department of Pharmaceutical Sciences

THE UNIVERSITY OF TENNESSEE, COLLEGE OF PHARMACY Memphis, Tennessee

2

I N T R O D U C T I O N

CONGRATULATIONS on your decision to pursue a career in the pharmaceutical sciences! We are very pleased that you are considering graduate studies at The University of Tennessee Health Science Center in Memphis. The purpose of this brochure is to provide you with information about the Department of Pharmaceutical Sciences. The brochure should tell you about some of the more important issues affecting your decision: academic opportunities, the faculty, research interests, and living in Memphis. You are cordially invited to arrange a visit to see our facilities and meet some of the faculty and students. M E S S A G E F R O M T H E A S S O C I A T E D E A N R E S E A R C H A N D G R A D U A T E P R O G R A M S

“We are very pleased that you are considering graduate studies in the pharmaceutical sciences and honored that you are thinking about pursuing those studies at The University of Tennessee. The Department of Pharmaceutical Sciences is composed of three divisions, Medicinal Chemistry, Pharmaceutics, and Health Outcomes and Policy Research. For further information on the Health Outcomes and Policy Research Program click on the following link: http://www.uthsc.edu/pharmacy/pharmsci/hopr/ Almost any avenue of study and research is available to you in these disciplines. In the Department we have a very diverse faculty dedicated to

excellence in teaching, research, and public service. Our College of Pharmacy has consistently been ranked among the top schools in the nation. As a graduate of our program, you have the ability to enter many different arenas: academia, industrial research, government service, and management, to name only a few. We believe our graduates are eminently qualified for whatever position they choose. I am pleased to provide this information about our program. Please let us know how we may help you make your decision about graduate studies at The University of Tennessee College of Pharmacy. If you have any questions, please don’t hesitate to ask any of the faculty members or myself. We look forward to meeting with you to discuss our excellent program.” BERND MEIBOHM, PHD Professor, Pharmaceutical Sciences Associate Dean, Graduate and Research Program 5P Crowe Memphis, TN 38163 901.448.1206

bmeibohm@uthsc.edu

3

E N D O W E D P R O F E S S O R S

DUANE D. MILLER, PH.D. HARRIETT S. VAN VLEET PROFESSOR OF PHARMACEUTICAL SCIENCES

A native of Larned, Kansas, Dr. Miller earned his Bachelor of Science degree in Pharmacy in 1966 from the University of Kansas and his Doctor of Philosophy degree in Medicinal Chemistry in 1969 from the University of Washington. He became a faculty member at Ohio State University in 1969. After eleven years, he was promoted to full professor, and, from 1983 to 1992, he served as chairman of the Department of Medicinal Chemistry at Ohio State. He was named Van Vleet Professor at the UT College of Pharmacy in 1992. Dr. Miller’s

research is focused on the relationship between chemical structure and biological activity of drug molecules, specifically working with drugs that affect the central and peripheral nervous systems. He was one of the co-discoverers of the new class of nonsteroidal selective androgen receptor modulators (SARMs). He is also interested in drugs that can be used to treat and prevent complications arising from diabetes and cancer. He is the author of over 200 articles, book chapters, and review articles. He holds many U.S. patents and has directed many graduate students and postdoctorals. David Rogers, PHARM.D. Ph.D. FIRST TENNESSEE CHAIR OF EXCELLENCE IN PEDIATRICS

Dr. David Rogers is Associate Dean for Translational Research for the College of Pharmacy, and Professor and Vice Chair for Research for the Department of Clinical Pharmacy at the University of Tennessee College of Pharmacy. He holds joint appointments in the Department of Pharmaceutical Sciences in the College of Pharmacy, as well as the Departments of Molecular Sciences and Pediatrics in the College of Medicine. Dr. Rogers completed his undergraduate work at the University of Memphis, received the Doctor of Pharmacy degree from

the University of Tennessee, and the Master of Science and Doctor of Philosophy degrees in Microbiology from the University of Mississippi. He completed an ASHP-accredited Residency in Pharmacy Practice at the Regional Medical Center at Memphis, as well as an ASHP-accredited Residency in Infectious Diseases Pharmacy Practice and Fellowship in Infectious Diseases Pharmacotherapy at the University of Mississippi Medical Center. Dr. Rogers is an elected Fellow of the American College of Clinical Pharmacy. He is the recipient of the 2002 Society of Infectious Diseases Pharmacists Young Investigator Award, the 2004 Society of Infectious Diseases Pharmacists Impact Paper in Infectious Diseases Pharmacotherapy Award, and the 2004 American College of Clinical Pharmacy Young Investigator Award. The objective of Dr. Rogers’ research program is to identify ways to improve currently available antifungal drugs as well as to identify novel approaches for treating invasive fungal infections. His current work focuses on the elucidation of the molecular basis of antifungal resistance and tolerance in the pathogenic fungi Candida albicans and Candida glabrata. Dr. Rogers’ research is supported through grants from associations, industry, and the National Institutes of Health. He has authored over 60 publications, and over 100 scientific abstracts to date.

4

T H E U N I V E R S I T Y

The University Of Tennessee, founded in 1794 in Knoxville, is Tennessee’s land grant university. From her humble beginnings over 200 years ago, The University is now home to over 40,000 students at four main campuses located in Knoxville, Memphis, Chattanooga, and Martin. Indeed, the entire State of Tennessee is the campus of the University. The three-fold mission of The University of Tennessee is teaching, research, and public service. The College of Pharmacy was founded in 1898 as part of the Science Department in Knoxville and moved to Memphis in the early 1900’s. UTHSC, the University’s health sciences campus, was established in 1911 as part of the UT System. The UTHSC campus has approximately 2,600 students enrolled in its six colleges. Of these, approximately 284 are graduate students. The six colleges on the Memphis campus are Allied Health Sciences, Dentistry, Graduate Health Sciences, Medicine, Nursing, and Pharmacy. T H E C O L L E G E O F P H A R M A C Y

The University of Tennessee College of Pharmacy enjoys one of the best reputations of any pharmacy school in the United States. The College was one of the first to grant the Doctor of Pharmacy (Pharm.D.) degree. The first all Doctor of Pharmacy (Pharm.D.) class was graduated in 1988. As reported in the U. S. News & World Report, deans and senior faculty from across the nation have consistently ranked the UT College of Pharmacy in the top twenty pharmacy schools nationwide. Everyone associated with the College – students, faculty, alumni, and staff -- is extremely honored and proud of these achievements, but they are also striving to improve on every aspect of the three-fold mission of the University and the College: teaching, research, and public service.

F A C I L I T I E S

The Department of Pharmaceutical Sciences is headquartered in the Pat and Joe Johnson Building, with additional offices and laboratories in the R. L. Crowe and Feurt Pharmacy Research Building. Research facilities of the Department are well equipped with contemporary scientific instrumentation (see specialized laboratories below). In addition, the University supports an excellent library, computer center, mass spectrometry center, vivarium, and biostatistics center. The 55-acre UTHSC campus is an integral part of one of the largest medical centers in the United States. The Memphis Medical Center area can roughly be defined as a six-block area located within blocks of downtown Memphis. The area contains one of the world’s largest private hospitals, Methodist Hospitals of Memphis. St. Jude Children’s Research hospital, founded by entertainer Danny Thomas, is the internationally-recognized hospital for the treatment of childhood cancers. The Veterans Affairs Medical Center is a 946-bed hospital affiliated with UTHSC. Just two blocks north of the campus is LeBonheur Children’s Medical Center, nationally known for its pediatric care. The Regional Medical Center at Memphis is a comprehensive hospital recognized for its Elvis Presley Memorial Trauma Center.

5

S P E C I A L I Z E D L A B O R A T O R I E S

DRUG DISCOVERY LABORATORIES

Molecular Modeling Laboratory

The Molecular Modeling Laboratory is designed to find and develop new pharmaceutical agents as well as to enhance activity of existing drugs. The Department has many Linux and SGI workstations running the Tripos software package, AMBER, and a variety of other software packages. The traditional development of chemotherapeutic agents involved the systematic synthesis of compounds and qualitative assessment of the structure-activity relationships. The utilization of molecular modeling techniques in drug development now permits the quantitative

determination of structure-activity relationship, conformational analysis of drug molecules, visualization of drug in the receptor/enzyme ligand binding pocket, and the in silica screening of combinatorial libraries against potential drug targets. Additionally, computational chemistry is utilized to develop models of proteins for which the structure is unknown as well as determine the reaction coordinates of chemical reactions.

Nuclear Magnetic Resonance Laboratory

The Department of Pharmaceutical Sciences has modern equipment for the performance of a wide range of experimental procedures. It consists of a Varian (now part of Agilent) Inova 500 MHz NMR and a Bruker Avance III 400M NHz NMR equipped with an automatic sample changer. The NMR lab is located in the Johnson Building. The 500MHz NMR is equipped with a Nano-probe, VAST, and three 5 mm probes. The 400M NMR is recently purchased by a NIH/NCRR instrument. These instruments are available to members of the Department for qualitative and quantitative purposes, and are presently being used to

determine the structures of drug molecules, the metabolic profiles of living cells, and the high-throughput screening of combinatorial libraries. Proton, carbon, phosphorous, fluorine and multinuclear capabilities, as well as multi-dimensional experiments are available.

LC-MS LABORATORY

The Bruker Esquire-LC ion Trap LC/MS(n) system is located in room 310, Johnson Building. Mass range (m/z) can be measured from 50 up to 6000 with high resolution and high sensitivity. Multiple fragmentation (MS/MS) of analyte molecule can go up to MS6 for structural elucidation. Coupled with HP 1100 Chemstation and the robust, versatile software running on Windows NT, the LC-MS system is an extremely powerful and indispensable instrument for life science and chemical research. The machine is currently available as an

open access resource for our students to use.

6

PARENTERAL MEDICATIONS LABORATORIES

The Parenteral Medication Laboratories are the result of a cooperative effort between The University of Tennessee and many private corporations who have special interests in injectable medications. Accordingly, private industry has generously contributed money and equipment to make these laboratories possible. The Laboratories contain a core processing area designed for academic instruction as well as for the processing of sterile dosage forms. It

provides the capacity for small-scale manufacturing of sterile preparations. The faculty and staff associated with the Parenteral Medications Laboratories are involved in development of sterile formulations, manufacture of small lots of product for clinical investigation, development and determination of stability of new sterile products, and development of biotech dosage forms. The Parenteral Medications Laboratories continue to provide hands-on training for the pharmaceutical industry in aseptic processing. Click on the link below for more information about the Parenteral Medications Laboratories: http://www.uthsc.edu/pharmacy/parenterals/

PHARMACEUTICAL RESEARCH DEVELOPMENT AND TRAINING LABORATORIES

The Pharmaceutical Research Development and Training Laboratories specialize in the research and development of conventional and controlled release dosage forms using state-of-the-art equipment. The laboratories are used to teach and train advanced undergraduate and graduate students and postdoctoral fellows. The laboratories are also used to do contract/research work for pharmaceutical, biotechnology and other health related industries. The graduate students, postdoctoral fellows and faculty are actively involved in all the research/contract projects as well as

in the postgraduate training program. The research interests of faculty and staff of The Pharmaceutical Research Development and Training Laboratories include: preformulation and formulation of solid dosage forms, including controlled release oral drug delivery systems, evaluation of compaction properties of excipients; development of new methodologies for non-destructive testing of solid and semisolid dosage forms; and formulation and development of biodegradable, injectable and implantable controlled release drug delivery systems for small molecules, as well as for macromolecules such as biologically active proteins and peptides. The following laboratories have several state-of-art pieces of equipment: PREFORMULATION LABORATORY A sonic sieve analyzer for particle size analysis from Gilson; dynamic flow measuring equipment from Hanson Research Corporation; moisture adsorption/desorption equipment from VTI Corp.; a differential scanning calorimeter from Perkin Elmer Corp.; and a helium pycnometer and surface area measurement equipment from Micromeritics, Inc.

7

FORMULATION LABORATORY

A roller compactor from Vector Corporation, several high-shear mixer granulators from Robot-Coupe, Inc.; an 18-stations instrumented tablet press attached to a fully automated and computer-controlled three-way tablet tester from Elizabeth-Hata International, Inc.; a fluid-bed dryer and coater from Glatt Air Techniques., Inc.,

QUALITY CONTROL/ANALYTICAL LABORATORY

Three HPLC systems equipped with photodiode array and refractive index detectors from Shimadzu; a near infrared spectroscopy equipment from Foss NIRSystems; USP dissolution and disintegration testers from Hanson Research Corporation and Distek Inc.; Rainbow dissolution tester from Delphian Technologies; a fully automated flow-through UV-visible spectrophotometer for dissolution testing from Perkin Elmer Corp.; a tensile strength tester from Ametek, Corp., and shaker-incubators from Labline Instruments. Click on the link below for more information about

the Pharmaceutical Research Development and Training Laboratories: http://www.uthsc.edu/pharmacy/pharmsci/tablettech/ PHARMACOKINETIS/PHARMACODYNAMICS RESEARCH LABORATORIES

CELL CULTURE LABORATORIES

Investigations of drug activity, metabolism, binding, protein/nucleic acid delivery and intracellular trafficking are often performed using isolated receptors or cultured cells. The Cell Culture Laboratory serves as the primary facility for these studies in the Department of Pharmaceutical Sciences. The laboratories consist of three temperature-and humidity-controlled rooms in the Johnson, Crowe and Feurt Buildings. The majority of research conducted in these laboratories is focused on the identification of compounds useful in the treatment of cancer as well as

for evaluation of novel polymeric carriers and gene expression systems for the treatment of diabetes, cancer and cardiovascular diseases.

8

G R A D U A T E F A C U L T Y DEPARTMENT OF PHARMACEUTICAL SCIENCES

MEDICINAL CHEMISTRY FACULTY

JOHN K. BUOLAMWINI, PHD Professor, Pharmaceutical Sciences 327C Johnson Memphis, TN 38163 901. 448.7533 jbuolamwini@uthsc.edu

ISAAC O. DONKOR, PHD Professor and Vice Chair, Pharmaceutical Sciences Associate Dean, Health Career Programs 327E Johnson Memphis, TN 38163 901.448.7736 idonkor@uthsc.edu

MICHIO KUROSU, PHD Associate Professor, Pharmaceutical Sciences 327A Johnson Memphis, TN 38163 901.448.1045 mkurosu@uthsc.edu

WEI LI, PHD Associate Professor, Pharmaceutical Sciences 327B/107 Johnson Memphis, TN 38163 901.448.7532 wli@uthsc.edu

DUANE D. MILLER, PHD Chair, Pharmaceutical Sciences Van Vleet Endowed Professor 227C Johnson Memphis, TN 38163 901.448.6026 dmiller@uthsc.edu

BOB M. MOORE, PHD Professor, Pharmaceutical Sciences 327D Johnson Memphis, TN 38163 901.448.6085 bmoore@uthsc.edu

9

PHARMACEUTICS FACULTY

HASSAN ALMOAZEN, PHD Assistant Professor, Pharmaceutical Sciences 205T Johnson Building Memphis, TN 38163 901.448.2239 halmoaze@uthsc.edu

SARKA BERANOVA-GIORGIANNI, PHD Assocaite Professor, Pharmaceutical Sciences 5P Crowe Memphis, TN 38163 901.448.5433 sberanova@uthsc.edu

JAMES R. JOHNSON, PHD. Associate Professor, Pharmaceutical Sciences 200 Feurt Building Memphis, TN 38163 901.448.4635 jmjohnson@uthsc.edu

VIVIAN S. LOVELESS, PHARM.D. Associate Professor, Pharmaceutical Sciences 227E Johnson Building Memphis, TN 38163 901.448.6931 vloveless@uthsc.edu

TAO L. LOWE, PHD Associate Professor, Pharmaceutical Sciences 227D Johnson Building Memphis, TN 38163 901.448.1087 Tlowe4@uthsc.edu

RAM MAHATO, PHD Professor, Pharmaceutical Sciences 224 Cancer Research Building Memphis, TN 38163 901.448.6929 rmahato@uthsc.edu

10

BERND MEIBOHM, PHD Professor, Pharmaceutical Sciences Associate Dean, Graduate and Research Program 5P Crowe Memphis, TN 38163 901.448.1206 bmeibohm@uthsc.edu

GEORGE C. WOOD, PHD Professor, Pharmaceutical Sciences 227D Johnson Memphis, TN 38163 901.448.2357 gwood@uthsc.edu

C. RYAN YATES, PHARMD, PHD Professor, Pharmaceutical Sciences 5P Crowe Memphis, TN 38163 901.448.4135 cyates4@uthsc.edu

FACULTY WITH PRIMARY APPOINTMENTS IN OTHER DEPARTMENTS William E. Evans, Pharm.D., FR-Professor* Lawrence J. Hak, Pharm.D., BCPS, FCCP Professor, Clinical Pharmacy Richard Lee, Ph.D., FR-Adjunct Professor* Mary V. Relling, Pharm.D., FR-Professor, Clinical Pharmacy* Erin Schuetz, Ph.D., FR-Adjunct Professor* John Schuetz, Ph.D., FR-Adjunct Professor* Scott E. Snyder, Ph.D., FR-Adjunct Associate Professor* Clinton F. Stewart, Pharm. D., FR-Adjunct Professor* Thomas R. Webb, Ph.D., FR-Adjunct Professor* *St. Jude

11

H A S S A N A L M O A Z E N , P H . D . Assistant Professor, Pharmaceutical Sciences

B.S. Pharmacy, Damascus University, Syria, 1991

Ph.D. (Pharmaceutics) Long Island University, 2002

Research Interests

Dr. Almoazen’s laboratory is involved in basic pharmaceutics and biophysical pharmacy. He has projects involved in the delivery of nanoemulsions to enhance drug permeability, evaluate the stability of nanocrystals and solid dispersions to enhance the solubility of poorly soluble therapeutic agents. He is also interested in the delivery of adjuvants that augment the immune response to vaccines.

Selected Publications

Hassan Almoazen, Anthony Samsa and Charlie C. May, “Why Analytical Testing is needed in Pharmaceutical Compounding” American Journal of Pharmacy Education, 74; (2); 2010: p 32c.

Hassan Almoazen, Himanshu Bhattacharjee, Anthony Samsa and Steve Pate “Stability of Mesna in Ready Med Infusion Devices” The Annals of Pharmacotherapy, 44; (1); 2010: P 224-225.

Hassan Almoazen and Anthony P. Simonelli. “Determining the Critical Micelle Concentration in O/W Emulsion Using the Rate Constant of Hydrolysis for Benzyl Acetate” Journal of Dispersion Science and Technology, Vol. 29; (7); 2008: P. 958-965.

Geoffrey Wall, Hassan Almoazen, and Erik Maki. “Lack of a Physicochemical Interaction between Metronidazole and Cholestyramine” International Journal of Antimicrobial Agents, October 30, (4), 2007: 372-4.

Madiha Sidhom, Nadya Rivera, Hassan Almoazen, David Taft, and Harold Kirschenbaum. “Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations” International Journal of Pharmaceutical Compounding, Vol. 9, No. 5, Sep/Oct 2005: 402-406.

Shoufeng Li, SuiMing Wong, Sundeep Sethia, Hassan Almoazen, Yatindra M. Joshi, and Abu T. M. Serajuddin. “Investigation of solubility and Dissolution of Free base and two different salt forms as a function of pH” Pharmaceutical Research, Vol. 22, No. 4, 2005: 628-635.

Ishani A. Savant, Michelle Kalis, Hassan Almoazen, Stephan R. Ortis, Malaz Abu Tarif and David R. Taft. “Alternative high-performance liquid chromatography assay for p-aminohippuric acid (PAH): effect of aging on PAH excretion in the isolated perfused rat kidney” Journal of Pharmaceutical and Biomedical Analysis, December 26, (5-6) 2001: 687-99.

12

S A R K A B E R A N O V A - G I O R G I A N N I , P H . D . Associate Professor, Pharmaceutical Sciences

M.S. (Chemistry), Prague Institute of Chemical Technology, Czechoslovakia, 1989.

Ph.D. (Analytical Chemistry), University of Akron, 1995

Research Interests

The research of Dr. Beranova-Giorgianni focuses on the application of mass spectrometry and proteomics to the study of human diseases. Current areas of interest include: (i) discovery of potential biomarkers and drug targets (prostate cancer; lung diseases); (ii) characterization of the phosphoproteome in human tissues (prostate; pituitary) and cultured cells (LNCaP); (iii) development and optimization of new proteomics methods that incorporate state-of-the-art mass spectrometry.

Selected Publications

Wang, X.; Tong, Y.; Giorgianni, F.; Beranova-Giorgianni, S.; Penn, J.S.; Jablonski M.M. Cellular

Retinol Binding Protein 1 Modulates Photoreceptor Outer Segment Folding In the Isolated Eye. Dev. Neurobiol 70, 623-635, 2010.

Chen, L.; Giorgianni, F.; Beranova-Giorgianni, S. Characterization of the Phosphoproteome in LNCaP Prostate Cancer Cells by in-gel Isoelectric Focusing and Tandem Mass Spectrometry. J. Proteome Res. 9, 174-178, 2010.

Nookala, S.; Gandrakota, R.; Wohabrebbi, A.; Wang, X.; Howell, D.E.; Giorgianni, F.; Beranova-Giorgianni, S.; Desiderio, D.M.; Jablonski, M.M. In Search of the Identity of the XAP-1 Antigen: A Protein Localized to Cone Outer Segments. Invest. Ophthalmol. Vis. Sci. 51, 2736-2743, 2010.

Beranova-Giorgianni, S.; Desiderio, D.M.; Giorgianni, F. Phosphoproteome Analysis by In-gel Isoelectric Focusing and Tandem Mass Spectrometry. Methods Mol. Biol. 519, 383-396, 2009.

Wang, X.; Narayanan, C.; Giorgianni, F.; Beranova-Giorgianni, S.; McCollum, G.; Gerling, I.C.; Penn, J.S.; Jablonski, M.M. Proteomic analysis of the retina: identification of key players in photoreceptor outer segment assembly. Glia 57, 380-392, 2009.

Pabst, M.J.; Pabst, K.M.; Handsman, D.B.; Beranova-Giorgianni, S.; Giorgianni, F. Proteome of monocyte priming by lipopolysaccharide, including changes in interleukin-1beta and leukocyte elastase inhibitor. Proteome Sci. 6:13, 2008.

Giorgianni, F.; Zhao, Y.; Desiderio, D.M.; Beranova-Giorgianni, S. Toward a global characterization of the phosphoproteome in prostate cancer cells: Identification of phosphoproteins in the LNCaP cell line. Electrophoresis 28, 2027-2934, 2007.

Beranova-Giorgianni, S; Zhao, Y; Desiderio, DM.; Giorgianni, F. Phosphoproteomic Analysis of the Human Pituitary. Pituitary 9, 109-120, 2006.

Zhao, Y; Giorgianni, F; Desiderio, DM; Fang B; Beranova-Giorgianni S. Analysis of the Proteome in Human Pituitary Tissue by Multiple Gel-Based Technology. Anal. Chem. 77, 5324-5331, 2005.

Giorgianni, F., Cappiello, A., Beranova-Giorgianni, S., Palma, P., Trufelli, H., Desiderio, D.M. LC-MS/MS Analysis of Peptides with Methanol as Organic Modifier: Improved Limits of Detection. Anal. Chem. 76, 7028-7038, 2004.

13

J O H N K . B U O L A M W I N I , P H . D . Professor, Pharmaceutical Sciences

B. Pharm. (Honors), University of Science and Technology, Ghana, 1981

Ph.D. (Medicinal Chemistry), University of Alberta, Canada, 1990

Research Interests Research in Dr. Buolamwini’s laboratory focuses on the design, synthesis, isolation and/or modification and evaluation of new molecules as potential therapeutic agents or pharmacological and biochemical research tools. Approaches used include computer-aided drug design by molecular modeling, including Docking (GLIDE, GOLD), 2D- and 3D-QSAR (CoMFA, CoMSIA, CATALYST, PHASE), as well as multivariate statistical analyses (PLS) and artificial neural networks, synthetic medicinal chemistry and chemical biology, combichem, cell and molecular biology, flow cytometry and radioisotope methods of analysis of ligand-receptor interactions. Molecular targets include nucleoside transporters, HIV integrase, EGFR, HER2, MDM2, GST-Pi and STAT3. Therapeutic areas include Ischemia-Reperfusion injury (coronary heart disease and stroke), Cancer

Chemotherapy and Chemoprevention, and HIV/AIDS Other Professional Editor-in-Chief, Current Cancer Drug Targets

Selected Publications Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF, Buolamwini JK. Synthesis, biological

evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorg. Med. Chem. Mar 1. (2011) [Epub ahead of print]

Wang C, Pimple S, Buolamwini JK. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. Biochem Pharmacol. 79, 307-320 (2010)

Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F. Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J. Biol. Chem. 284, 16979-16989 (2009)

Lin W, Buolamwini JK. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J. Med. Chem. 50, 3906-3920 (2007)

Zhu Z, Hofmann PA, Buolamwini JK. Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. Am J Physiol Heart Circ Physiol. 292, H2921-H2926 (2007)

Patil S, Kamath S, Sanchez T, Neamati N, Schinazi RF, Buolamwini JK. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem. 15, 1212-1228 (2007)

14

I S A A C O . D O N K O R , P H . D . Professor And Vice Chair, Pharmaceutical Sciences

Director of Graduate Programs

B. Pharm. (Honors), University of Science and Technology (Ghana), 1978

Ph.D. (Medicinal Chemistry), Duquesne University, 1988

Research Interest

Dr. Donkor’s laboratory is involved in the design, synthesis, and evaluation of enzyme inhibitors and DNA interactive agents as potential therapeutic agents. The laboratory is currently focused on discovery of potent and selective inhibitors of calpain. Calpain is a calcium activated cysteine protease with several known isoforms. The enzyme is an important modulator of a number of physiological and pathological events hence, it is considered a potential drug target. The laboiratory is probing the subsites of calpain to determine structural differences between the major calpain isoforms (calpains 1 and 2) with the goal of developing calpain isoform selective inhibitors. Additionally, the laboratory is investigating allosteric

sites on calpain for development of nonpeptide allosteric inhibitors of the enzyme. Selected Publications

I.O. Donkor. “Calpain inhibitors: a survey of compounds reported in the patent and scientific literature”. Exp. Opin. Ther. Pat. 21, 1-36 (2011) (Invited Review).

J.J. Sampson III, I.O. Donkor, T.L. Huang, and S.E. Adunyah. “Novel piperazine induces apoptosis in U937 cells”. Int. J. Biochem. Mol. Biol. 2, 78-88 (2011).

I.O. Donkor and R. Korukonda. “Synthesis and calpain inhibitory activity of peptidomimetic compounds with constrained amino acids at the P2 position”. Bioorg. Med. Lett. 18, 4806-4808 (2008).

I.O. Donkor, H. Assafa and J. Liu. “Structural basis for the potent calpain inhibitory activity of peptidyl α-ketoacids”. J. Med. Chem., 51, 4346-4350 (2008).

T.L. Huang, C.J. Bacchi, N.R. Kode, Q. Zhang, G. Wang, N. Yartlet, D. Rattendi, I. Londono, L. Mazumder, J.J.V Eynde, A. Mayence, and I.O. Donkor. “Trypanocidal activity of piperizine-linked bisbenzamidines and bisbenzamidoxine, an orally active prodrug.” Int. J. Antimicrob. Agents, 30, 555–561 (2007).

R. Korukonda, J. Liu, N. Guan, J.T. Dalton, and I.O. Donkor. “Synthesis, calpain inhibitory activity,

and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl -ketoamides”. J. Med. Chem., 49, 5282-5290 (2006).

N. Guan, R. Korukonda, E. Hurh, T.D. Schmittgen, I.O. Donkor, and J.T. Dalton. “Apoptosis induced by novel aldehyde calpain inhibitors in human tumor cell lines”. Int. J. Oncol. 29, 655-663 (2006).

T.L. Huang, J.J.V. Eynde, A. Mayence, I.O. Donkor, S.I. Khan, and B.L. Tekwani. “Antiplasmodial and antileishmanial activities of conformationally restricted pentamidine congeners.” J. Pharm. Pharmacol., 58, 1033-1042 (2006).

M.L. Sanders and I.O. Donkor. “Peptidomimetic calpain inhibitors incorporating P2-aza-amino acids”. Bioorg. Med. Chem. Lett. 16, 1965-1968 (2006).

Book Chapters The APhA Complete Review for the FPGEE (Chapter 8).

15

J A M E S R . J O H N S O N , P H . D . Associate Professor, Pharmaceutical Sciences

Director, Pharmaceutical Research, Development and Training Laboratories

B.S.Pharmacy, University of Minnesota, 1962

M.S., University of Minnesota, 1968 Ph.D., University of Minnesota, 1968

Research Interest

The Pharmaceutical Research Development and Training Laboratories specialize in the research and development of conventional and controlled release dosage forms using state-of-the-art equipment. The laboratories are used to teach and train undergraduate and graduate students, postdoctoral fellows as well as over 100 industry personnel annually. The laboratories are also used to conduct contract/research work for pharmaceutical, biotechnology and other health related industries. The graduate students, postdoctoral fellows and faculty are actively

involved in the research/contract projects as well as in the postgraduate training program.

Selected Publications

S. Yu, X. Zhang, Y. Sun, Y. Peng, J. R. Johnson, T. Mandrell, A. J. Shukla, and S. C. Laizure, Pharmacokinetics of buprenorphine after intravenous administration in the mouse, Journal of the American Association for Laboratory Animal Science : JAALAS, 45 (3), p.12-16, May 2006.

Y. Sun, D. Scruggs, Y. Peng, J. R. Johnson and A. J. Shukla, Issues and challenges in developing long-acting antibiotic formulations, Advanced Drug Delivery Reviews, 56 (10), p.1481-1496, Jun 2004

Y. Sun, Y. Peng, N. Aksornkoae, J. R. Johnson, J. G. Boring, D. Scruggs, R. C. Cooper, S. C. Laizure and A. J. Shukla, Controlled release of oxytetracycline in sheep, Journal of Controlled Release, 2002 13 (85) (1-3) 125-34.

Sun Y, Watts DC, Johnson JR and Shukla AJ, Biodegradable drug delivery systems, American Pharmaceutical Review, 4 (4) 25-30, 2001.

Sun Y, Watts DC, Johnson JR and Shukla AJ., Biodegradable Polymers and their degradation mechanisms, American Pharmaceutical Review, 4 (3) 8-18, 2001.

Abstracts: S. Bedi, S. Shukla, J. Johnson, E. Brunson, H. Bhattacharjee, H. Almoazen, Preparation and

Characterization of PLGA Microspheres Incorporated with Materials Having Surface Affinity to Achieve High Encapsulation Efficiency of a Peptide Drug with Minimized Rapid Initial Drug Release, American Association of Pharmaceutical Scientists 2010 annual meeting, New Orleans, LA.

W. Qu, Y. Sun, A. Soscia, P. Jain, Y. Peng, E. Brunson, H. Almoazen, A. Shukla, J. Johnson, Abuse-resistant Immediate Release Oxycodone Formulation, American Association of Pharmaceutical Scientists 2010 annual meeting, New Orleans, LA.

W. Wu, C. Egger, J. Xu, J. Johnson, A. Shukla, Development of Sustained Release Buprenorphine Formulations for Dogs, American Association of Pharmaceutical Scientists 2009 annual meeting, Los Angeles, CA.

16

M I C H I O K U R O S U , P H . D . A s s o c i a t e P r o f e s s o r , P h a r m a c e u t i c a l S c i e n c e s

B.S. (Organic&Bioorganic Chemistry/Pharmacy), Tokyo Univ. of Pharmacy and Life Science (Japan), 1990 M.S. (Organic Chemistry/Pharmacy), Osaka University (Japan), 1992

Ph.D. (Organic Chemistry/Pharmacy/Pharmacology), Osaka University (Japan), 1995

Research Interest: Infectious Filed: Our group has a long-term interest in development of new

antibacterial agents targeting novel or unexploited drug targets. In order to develop novel antibacterial molecules, we develop concise syntheses of complex molecules, designs chiral molecules, and generate small optimized libraries. We also design convenient assays against the target enzymes of interest. These efforts have resulted in the discovery of several new drug leads effective against MDR-Gram-positive pathogens including MDR-M. tuberculosis (Mtb). Over the last 5 years, we have studied on unexploited peptidoglycan biosynthesis (MraY) and their inhibitor molecules, and selective electron transport system inhibitors. Cancer Research: We have been interested in

eukaryotic inhibition factors (eIFs), protein synthesis inhibitors, and topoisomerase inhibitors. Our primary efforts are to develop concise synthesis of validated molecules and to generate small optimized libraries. Early Diagnosis of Cancer: We have been developing new molecular imaging tools via magnetic resonance imaging (MRI). Selected Publications

Vitamin K2 in Electron Transport System: Are Enzymes Involved in Vitamin K2 Biosynthesis Promising Drug Targets?, Kurosu, M.; Begari, E. Molecules, 2010, 15, 1531-1553.

Bacterial Protein Kinase Inhibitors. Kurosu, M.; Begari, E. Drug Development Research 2010, 71, 168-187.

A Concise Synthesis of Capuramycin. Kurosu, M.; Li, K.; Crick, D. C. Org. Lett. 2009,11, 2393. New Chiral Derivatizing Agents: Convenient Determination of Absolute Determination of Free

Amino Acids by 1H-NMR, Kurosu, M.; Li, K. Org. Lett. 2009, 11, 911. Highly Efficient O-Glycosylations with p-Tolyl thioriboside and p-TolSOTf. Kurosu, M.; Li, K. J. Org.

Chem. 2008, 73, 9767. MenA Is a Promising Drug Target for Developing Novel lead Molecules to Combat

Mycobacterium tuberculosis, Kurosu, M.; Crick, D. C. Medicinal Chemistry 2009, 5, 197-207. Multiple-delayed Release Formulation Approach for the treatment of Methicillin-resistant

Staphylococcus aureus. Kurosu, M. Expert Opinion Patent Evaluation 2008, 18, 1313-1322. Polymer-Supported (2,6-Dichloro-4-alkoxyphenyl)(2,4-dichlorophenyl)methanol: A New Linker

for Solid-Phase Organic Synthesis, Kurosu, M.; Biswas, K.; Crick, D. C. Org. Lett. 2007, 9, 1141-1444.

Fe/Cr-and Co/Cr Mediated catalytic Asymmetric 2-Haloallylations of Aldehydes, Kurosu, M.; Lin, M-H.; Kishi, Y, J. Am. Chem. Soc. 2004, 126, 12248-12249.

Representative Patents Compositions and Methods of Use of Electron Transport System Inhibitors Serial Number: PCT /

US 2007 / 63122, Kurosu, M. et.al. Books and Book Chapters

Electrophile cleavable linker unit In Linker Strategies in Solid-Phase Organic Synthesis (2009), 27-76, John Wiley and Sons, Ltd, 2009 (October).

17

W E I L I , P H . D .

Associate Professor and Director of NMR Facility

BS, Chemistry, Univ. of Sci. & Technol. of China, 1992

PhD, Chemistry, Columbia University, 1999

Research Interest

The research in our lab is highly multi-disciplinary and often involves collaboration with other labs. Currently research in our group broadly focuses on the following three areas: 1) Discovery of novel therapeutic agent for melanoma; 2) Discovery of novel vitamin D analogs as potential therapeutic agents; and 3) Application of NMR spectroscopy, especially high resolution magic angle spinning NMR (HRMAS NMR) techniques, in drug discovery studies. Techniques used in our lab include extensive molecular

modeling, organic synthesis, in vitro and in vivo biological assay, and nanotechnology based drug delivery approaches. For more information about the group including recent publications, please visit our lab homepage.

Selected Publications

Andrzej Slominski, Wei Li, Syamal K. Bhattacharya, Jianjun Chen, Robert C Tuckey, Duane Miller, Arnold E. Postlethwaite, "Novel Vitamin D Analogues 20,23(OH)2D3 and 17,20(OH)pD are Noncalcemic and Biologically Active", J Invest Dermatol., in press, PMID: 21228816, (2011).

Chien-Ming Li#, Zhao Wang#, Yan Lu, Wei Li*, Sunjoo Ahn, Ramesh Narayanan, Jeffrey D. Kearbey, Deanna N. Parke, Duane D. Miller, James T. Dalton*, “Biological activity of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART): An active microtubule inhibitor”, Cancer Res, 71(1), 216-224, (2011). (# equal contributions; * Li and Dalton are corresponding authors).

Andrzej T. Slominski, Zorica Janjetovic, Brian E. Fuller, Michal A. Zmijewski, Robert C. Tuckey, Minh N. Nguyen,Trevor Sweatman, Wei Li, Jordan Zjawiony, Duane Miller, Tai C. Chen, Gerard Lozanski, Michael F. Holick, “Novel products of vitamin D3 or pro-vitamin D3 (7-dehydrocholesterol) metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity”, PLOS One, 5(3):e9907 (2010).

Wei Li, Jianjun Chen, Zorica Janjetovic, Tae-Kang Kim, Trevor Sweatman, Yan Lu, Jordan Zjawiony, Robert C Tuckey, Duane Miller, Andrzej Slominski, “Chemical Synthesis of 20S-hydroxyvitamin D3, which shows anti-proliferative activity”, Steroids, 75(12):926-35, (2010).

Jianjun Chen, Zhao Wang, Chien-Ming Li, Yan Lu, James T. Dalton, Duane D. Miller, Wei Li, “Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting tubulin polymerization as potential agents for resistant cancer treatment”, J. Med. Chem., 53 (20), pp 7414–7427, (2010).

Yan Lu, Chien-Ming Li, Zhao Wang, Charles R. Ross, II, Jianjun Chen, James Dalton, Wei Li and Duane. D. Miller, "Discovery of 4-Substituted Methoxybenzoyl-Aryl-Thiazole as Novel Anticancer Agents: Synthesis, Biological Evaluation and Structure-Activity Relationships", J. Med. Chem., 52(6):1701-1711, (2009).

Zhao Wang, Yan Lu, William Seibel, Duane D. Miller, and Wei Li, “ Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening”, J. Chem. Info. Model., 49(6):1420-7, (2009).

18

V I V I A N S . L O V E L E S S , P H A R M . D . , B C N P , F A P h A Associate Professor

B.S., The University of Tennessee College of Pharmacy, 1975

Pharm. D., The University of Tennessee College of Pharmacy, 1976 Residency in Nuclear Pharmacy, The University of Tennessee College of Pharmacy, 1977

Research Interest

Research interest is in the area of traditional radiopharmaceuticals, positron emission tomography (PET) radiopharmaceuticals, and interventional agents used in nuclear medicine.

Selected Publications

VS Loveless, CP Surdock, H Bhattacharjee. Evaluation of zeta-potential and particle size of technetium 99mTc-sulfur colloid subsequent to the addition of lidocaine and sodium bicarbonate. J Nucl Med Technol, 2010:38:49-52.

VS Loveless. Quality control of compounded radiopharmaceuticals. Continuing Education for Nuclear Pharmacists and Nuclear Medicine Professionals, The University of New Mexico Health Sciences Center College of Pharmacy, Albuquerque, NM. 2009;15(3).

V Loveless. Nuclear Medicine Imaging in the Pediatric Patient. J Pediatr Pharmacol Ther, 2006;11:200-211.

VS Loveless. Drugs Used as Interventional Agents in Nuclear Medicine. Continuing Education for Nuclear Pharmacists and Nuclear Medicine Professionals, The University of New Mexico Health Sciences Center College of Pharmacy, Albuquerque, NM. 1998;7(2).

JF Rockett, HL Magill, VS Loveless and GL Murray. Intravenous Dipyridamole Thallium-201 SPECT Imaging Methodology, Applications and Interpretations. Clin Nucl Med, 1990:15;712-25.

J Rockett, WC Wood, M Moinuddin, VS Loveless and B Parrish. Intravenous Dipyridamole Thallium-201 SPECT Imaging in Patients with Left Bundle Branch Block. Clin Nucl Med, 1990:15;401-7.

CR Morris, LH Blackwell and VS Loveless. Antileukemic Properties of Combinations of Radiation and Malonato (1,2-diaminocyclohexane) Platinum (II). (NSC-224964). J Med, 1977:8;253-59.

19

T A O L . L O W E , P H . D . Associate Professor, Pharmaceutical Sciences

Ph.D., Polymer Chemistry, Eximia Cum Laude, University of Helsinki, Finland, 1998

Postdoctoral Associate, Chemical Engineering, University of Wisconsin, Madison, 1999-2001

Research Interest

In Dr. Lowe’s state-of-the-art “Biomaterials for Translational Research Laboratory”, the research features innovative bionanotechnology, drug delivery, gene therapy, tissue engineering, and biosensor. The research activities include rational design and synthesis of multi-stimuli-responsive polymeric biomaterials including nanogels, branched nanoparticles, hydrogels and thin films; characterizations of the mechanisms by which the designed biopolymers regulate targeted and sustained delivery of drugs, proteins and genes, promote cell growth, and provide biosensing; and in vitro and in vivo studies of the bioefficacy of these biomaterials. The ultimate goal of the research in Dr. Lowe’s lab is to develop novel biomaterials that can

provide exquisitely sensitive, selective, non-toxic, biodegradable and responsive platforms to target therapeutic agents to the sites of ocular, central nervous, cancerous, or musculoskeletal lesions.

Selected Publications

Yuan W, Li G, Gil ES, Lowe TL, Fu BM. Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Annals of Biomedical Engineering 38(4):1463-72, 2010. PMID: 20087768.

Misra GP, Singh RS, Aleman TS, Jacobson SG, Gardner TW, and Lowe TL. Subconjunctivally Implantable Hydrogels with Degradable and Thermoresponsive Properties for Sustained Release of Insulin to the Retina. Biomaterials 30(33):6541-6547, 2009. PMID: 19709741. NIHMS138962.

Gil ES, Li JS, Xiao HN and Lowe TL. Quaternary Ammonium β-Cyclodextrin Nanoparticles for Enhancing Doxorubicin Permeability across the in vitro Blood Brain Barrier. Biomacromolecules 10(3): 505-516, 2009. PMID: 19216528.

Huang X, Misra GP, Vaish A, Flanagan JM, Sutermaster B and Lowe TL. Emulsion Polymerization of Both Hydrolytically Degradable and Thermoresponsive Nanogels without Using Low Molar Mass Surfactants. Macromolecules 41 (22): 8339-8345, 2008.

Stover TC, Kim YS, Lowe TL and Kester M. Thermoresponsive and Biodegradable Linear-Dendritic Nanoparticles for Targeted and Sustained Release of a Pro-apoptotic Drug. Biomaterials 29 (3): 359-369, 2008. PMID: 17964645.

Huang X, Zhang Y, Donahue HJ and Lowe TL. Porous Thermoresponsive-co-Biodegradable Hydrogels as Tissue Engineering Scaffold for 3-D in Vitro Culture of Chondrocytes. Tissue Engineering 13 (11): 2645-2652, 2007. PMID: 17683245.

Kim YS, Gil ES and Lowe TL. Synthesis and Characterization of Thermoresponsive-co-Biodegradable Linear-Dendritic Copolymer. Macromolecules 39 (23): 7805-7811, 2006.

Huang X and Lowe TL. Biodegradable Thermoresponsive Hydrogels for Aqueous Encapsulation and Controlled Release of Hydrophilic Model Drugs. Biomacromolecules 6(4): 2131-2139, 2005. PMID: 16004455.

Kim YS, Lim JY, Donahue HJ and Lowe TL. Thermoresponsive Terpolymeric Films Applicable for Osteoblastic Cell Growth and Noninvasive Cell Sheet Harvesting. Tissue Engineering 11(1-2): 30-40, 2005. PMID: 15738659.

20

R A M M A H A T O , P H . D . Professor, Pharmaceutical Science

B.S. (Pharmaceutics), China Pharmaceutical University, China, 1989

Ph.D. (Pharmaceutics/Drug Delivery), University of Strathclyde, Britain, 1992

Research Interest

Dr. Mahato’s laboratory is involved in: (i) design and synthesis of polymers and lipids for delivery and targeting of small molecules, oligonucleotides, siRNA and genes; (ii) design and construction of gene/shRNA expression systems; (iii) formulation and in vitro Characterization of Nucleic Acid Delivery Systems, (iv) Micellar delivery of small molecule drugs; (v) Bioconjugation and particulate carrier systems for treating a) liver fibrosis, ischemia reperfusion liver injury, prostate cancer and diabetes; (vi) Mesenchymal stem cells as gene delivery vehicles for improved islet transplantation; and (vii) mechanisms of cellular uptake and

intracellular trafficking of nucleic acid drugs, (viii) gene/siRNA delivery to human pancreatic islets. Selected Publications

Zhu L, Mahato RI (2010) Targeted Delivery of siRNA to Hepatocytes and Hepatic Stellate Cells by Bioconjugation. Bioconjug Chem. 21: 2119-2127.

Li F, Danquah M and Mahato RI (2010) Synthesis and Characterization of Amphiphilic Lipopolymers for Micellar Drug Delivery. Biomacromolecules 11: 2610-20.

Pratap A, Panakanti R, Yang N, Eason JD and Mahato RI Inhibition of Endogenous Hedgehog Signaling Protects against Acute Liver Injury after Ischemia Reperfusion. Pharm Res 27: 2492-504.

Danquah M, Fujiwara T, Mahato RI (2010) Self-assembling methoxypoly (ethylene glycol)-b-poly(carbonate-co-l-lactide) block copolymers for drug delivery. Biomaterials. 31: 2358–2370.

Yang N, Ye Z, Li F and Mahato RI (2009) HPMA Polymer-based Site-specific Delivery of Oligonucleotides to Hepatic Stellate Cells. Bioconjugate Chem 20:213-221.

Panakanti R and Mahato RI (2009) Bipartite Adenoviral Vector encoding hVEGF and hIL-1Ra for Improved Human Islet Transplantation. Mol Pharm6: 274-284.

Chen Y and Mahato RI (2008) siRNA Pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target 16:140-148.

Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific triple helix formation with genomic DNA. Biochemistry 46: 11240-11252.

Narang AS, Cheng K, Henry J, Zhang C, Sabek O, Fraga D, Kotb M, Gaber AO and Mahato RI (2004) Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation. Pharm Res.21:15-25.

Wang D-A, Narang AS, Kotb M, Gaber OA, Miller DD, Kim SW and Mahato RI (2002) Novel branched poly(ethylenimine)-cholesterol water soluble lipopolymers for gene delivery. Biomacromolecules 3: 1197-1207.

21

B E R N D M E I B O H M , P H . D . , F . C . P . Professor, Pharmaceutical Sciences

Associate Dean, Graduate and Research Program

B.S. (Pharmacy), Technical University Carolo-Wilhelmina, Braunschweig, Germany, 1989

Ph.D. (Pharmaceutics), Technical University Carolo-Wilhelmina, Braunschweig, Germany, 1994

Research Interest

Dr. Meibohm’s research is focused on the investigation of the pharmacokinetics (PK), pharmacodynamics (PD) and pharmacogenetics (PG) of drugs with special emphasis on PK/PD/PG-correlations. Areas of interest include chronic inflammatory processes (e.g., COPD), transplantation, pediatric pharmacotherapy and preclinical and clinical drug development, especially of biotechnology drugs. The ultimate goal of the research in Dr. Meibohm’s lab is to contribute to the optimization of dosing regimens for increased efficacy and reduced toxicity and to

modulate pharmacotherapy according to the needs of the individual patient. Selected Publications

Dirks, NL, Meibohm, B. Population Pharmacokinetics of Therapeutic Monoclonal Antibodies. Clinical Pharmacokinetics 2010, 49, 633-59.

Kumar, R, Seibold, MA, Aldrich, MC, Williams, LK, Reiner, AP, Colangelo, L, Galanter, J, Gignoux, C, Hu, D, Sen, S, Choudhry, S, Peterson, EL, Rodriguez-Santana, J, Rodriguez-Cintron, W, Nalls, MA, Leak, TS, O'Meara, E, Meibohm, B, Kritchevsky, SB, Li, R, Harris, TB, Nickerson, DA, Fornage, M, Enright, P, Ziv, E, Smith, LJ, Liu, K, Burchard, EG. Genetic ancestry in lung-function predictions. New England Journal of Medicine 2010, 363(4), 321-30.

Vaddady, PK, Lee, RE, Meibohm, B. In Vitro Pharmacokinetic/Pharmacodynamic Models in Anti-infective Drug Development: Focus on Tuberculosis. Future Medicinal Chemistry 2010, 2, 1355-69.

Suryawanshi, S, Zhang, L, Pfister, M, Meibohm, B. The current role of model-based drug development. Expert Opinion on Drug Discovery 2010, 5, 311-21.

Mehrotra, N, Tolley, EA, Bauer, DC, Harris, TB, Newman, AB, Kritchevsky, SB, Meibohm, B. Predictors of Mortality in Elderly Subjects with Obstructive Airway. Annals of Epidemiology 2010, 20, 223-32.

Laer, S, Barrett, JS, Meibohm, B. The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy. Journal of Clinical Pharmacology 2009, 48, 889-904.

Zhang, L, Pfister, M, Meibohm, B. Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development. AAPS Journal 2008, 10, p. 552-9.

Zhang, Y, Mehrotra, N, Budha, NR, Christensen, ML, Meibohm, B. A Tandem Mass Spectrometry Assay for the Simultaneous Determination of Acetaminophen, Caffeine, Phenytoin, Ranitidine, and Theophylline in Small Volume Pediatric Plasma Specimens. Clinica Chimica Acta 2008, 398, p. 105-12.

Budha, NR, Lee, RE, Meibohm, B. Biopharmaceutics, Pharmacokinetics and Pharmacodynamics of Antituberculosis Drugs. Current Medicinal Chemistry 2008, 15, p. 809-25.

22

D U A N E D . M I L L E R , P H . D . VAN VLEET PROFESSOR

Chair, Pharmaceutical Sciences

B.S. in Pharmacy, University of Kansas, 1966

Ph.D. (Medicinal Chemistry), University of Washington, 1969

Research Interest

Dr. Miller has several research interests including: the design and synthesis of beta-3 adrenergic antagonists for the treatment of obesity; imidazoline analogs as molecular probes of the adrenergic receptors; nonsteroidal selective androgen receptor modulators (SARMs); aldose reductase inhibitors; anticancer (glioma) agents and new phospholipid agents for the interaction with LPA (EDG) receptors.

Selected Publications Lu, Y, Li, CM, Wang, Z, Ross, CR, Chen, J, Dalton, JT, Li, W, Miller, DD. Discovery of 4-substituted

methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem, 52 (6), 1701-11, 2009.

Zmijewski, MA, Li, W, Zjawiony, JK, Sweatman, TW, Chen, J, Miller, DD, Slominski, AT. Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids, 74 (2), 218-28, 2009.

Ramagiri, S, Ma, F, Kosanam, H, Wang, X, Patil, R, Miller, DD, Geisert, E, Yates, CR. Fast and sensitive liquid chromatography/electrospray mass spectrometry method to study ocular penetration of EDL-155, a novel antitumor agent for retinoblastoma in rats. J Mass Spectrom, 2009.

Mohler, ML, He, Y, Wu, Z, Hwang, DJ, Miller, DD. Recent and emerging anti-diabetes targets. Med Res Rev, 29 (1), 125-95, 2009.

Zmijewski, MA, Li, W, Zjawiony, JK, Sweatman, TW, Chen, J, Miller, DD, Slominski, AT. Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci, 7 (12), 1570-6, 2008.

DeCuypere, M, Lu, Y, Miller, DD, LeDoux, MS. Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. J Neurochem, 107 (5), 1398-413, 2008.

Zhu, L, Lu, Y, Miller, DD, Mahato, RI. Structural and formulation factors influencing pyridinium lipid-based gene transfer. Bioconjug Chem, 19 (12), 2499-512, 2008.

Narayanan, R, Coss, CC, Yepuru, M, Kearbey, JD, Miller, DD, Dalton, JT. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol, 22 (11), 2448-65, 2008.

Kang, GS, Wang, XD, Mohler, ML, Kirichenko, OV, Patil, R, Orr, WE, Miller, DD, Geisert, EE. Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma. Anticancer Drugs, 19 (9), 859-70, 2008.

DeCuypere, M, Kalabokis, VN, Hao, R, Schroeder, D, Miller, DD, LeDoux, MS. Localization of N-methyl-norsalsolinol within rodent and human brain. J Neurosci Res, 86 (11), 2543-52, 2008.

23

B O B M . M O O R E I I , P H . D . Professor, Pharmaceutical Sciences

B.S. (Chemistry), Indiana State University, 1983 M.S. (Chemistry), Indiana State University, 1989

Ph.D. (Medicinal Chemistry), University of Kansas, 1995

Research Interest

Research in Dr. Moore’s lab integrates synthetic organic chemistry, computational chemistry and in vivo and in vitro assays aimed at developing new chemotherapeutic entities. The current areas of research include: development of cannabinoid receptor (CB1 and CB2) agonist and antagonist for the treatment of cancer; hemorrhagic shock; and immune regulation. The anti-cancer activity of cannabinoid based therapeutics is one of the most promising areas in antineoplastic development owing to the low in vivo toxicity and broad spectrum activity. The significance of cannabinoid based cancer therapeutics is exemplified

by the efficacious activity of Dr. Moore’s cannabinoid ligands against cancer stem like cells. This subpopulation of cancer cells is increasing being linked to metastasis and drug resistance, the ultimate cause of mortality in cancer patients. Selected Publications

1. H. Bhattacharjee, A. Nadipuram, S. Kosanke, M. Kiani, B.M. Moore B.M. II, “Low Volume Binary Drug Therapy for the Treatment of Hypovolemia.” Shock, 2011, in press.

2. P.K. Vaddady, N. Mehrotra, X. Zhang, C.R. Yates, B.M. Moore, B. Meibohm, “Pharmacokinetics of a combination of Δ(9) -Tetrahydro-cannabinol and celecoxib in a porcine model of hemorrhagic shock.” Biopharm. Drug Dispos. 2011, 32, 89.

3. H. Bhattacharjee, S. Gurley, P. Allison, X. Zhang, B. M. Moore II, “Evaluation of Novel Vanilloid Based Hemostatic Agents in Rats” J. Trauma 2010, 68, 676.

4. A. M. Ferreira, M. Krishnamurthy, B. M. Moore, II, D. Finkelstein, D. Bashford, “Quantitative Structure-Activity Relationship (QSAR) for a Series of Novel Cannabinoid Derivatives Using Descriptors Derived from Semi-empirical Quantum Chemical Calculations.” Bioorg. Med. Chem. 2009, 17, 2598.

H. Bhattacharjee, S.Gurley, B. M. Moore II, “Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands” Bioorg. Med. Chem. Lett. 2009, 19, 1691.

M. Krishnamurthy, S. Gurley, and B. M. Moore II, “Exploring the Substituent Effects on a Novel

Series of C1'-Dimethyl-Aryl 8-Tetrahydrocannabinol Analogs. Bioorg. Med. Chem. 2008, 16, 6489.

24

G E O R G E C . W O O D , P H . D . Professor, Pharmaceutical Sciences

B.S. (Pharmacy), University of Illinois Medical Center, Chicago, 1965

M.S. (Pharmaceutics), University of Illinois Medical Center, Chicago, 1968 Ph.D. (Pharmaceutics), University of Illinois Medical Center, Chicago 1970

Research Interest

Dr. Wood’s research interest includes development of biotechnology based, parenteral dosage forms. He is also interested in educational assessment of pharmacy student performance.

Selected Publications

Y. Mi, G.Wood, Y. Gao, B. Bothner, R. Ray, L. Thoma. Freeze thaw protection mechanisms of polyethylene glycols on lactate dehydrogenase. AAPS Annual Meeting 2001.

Y. Mi, G. Wood, L. Thoma. Cryoprotection of polyethylene glycols on lactate dehydrogenase

activity and secondary structure. PDA Annual Meeting 2001.

G. Wood, N Aksornkoae and L Thoma. Evaluation of an oxygen extraction device in slowing oxidative epinephrine degradation. Parenteral Drug Association National Meeting, Washington, D.C. November, 1998.

G. Wood. Lyophilization of protein drugs. Nycomed Pharmaceutical Company, Barcelonetta,

Puerto Rico, 6 hours, May, 1998.

G. Krishna, G. C. Wood, and B. B. Sheth. Improving emulsification efficacy of lecithin by formulation design K: Effect of adding a secondary surfactant. Pharm. Res. 13, (9), S-217 (1996).

G.C. Wood, M.R. Iyer, A.M. Geller, A.M. Fleischner, B.B. Sheth. An HPLC method for analysis of

deslorelin and and benzyl alchol in deslorelin injection. Pharm. Res. 10, 66 (1993).

25

C . R Y A N . Y A T E S , P H A R M . D . , P H . D . Professor, Pharmaceutical Sciences

Coordinator Of Dual Degree Program

Pharm.D. (Pharmacy), The University of Tennessee, Memphis, 1997

Ph.D., (Pharmaceutics), The University of Tennessee, Memphis, 2000

Research Interest

Dr. Yates' research is focused on the discovery and development of anti-inflammatory drugs. His platform technology, based upon the quinic acid derivative KZ-41, has demonstrated radiomitigating activity in a murine model of the hematopoietic acute radiation syndrome (ARS). Moreover, his laboratory is investigating the genomic basis for susceptibility to injury following high dose radiation exposure using BXD mice as a human population genetics model. Our overall goal is to elucidate the mechanism of action of our radiomitigant platform and to identify novel molecular pathways/targets critical to the radiation injury response.

Selected Publications

Gupte R, Patil R, Lu J, Wang Y, Lee SC, Fujiwara Y, Bolen AL, Emmons-Thompson K, Yates CR, Siddam A, Panupinthu N, Pham TC, Baker DL, Parrill AL, Mills GB, Tigyi G, and Miller DD. Benzyl and naphthalene-methyl phosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic actions. BMCL (2011).

Patil R, Wang X-D, Orr WE, Yates CR, Geisert EE, and Miller DD. Synthesis and antiglioma activity of new tetrahydroisoquinolines. Med Chem Res 2011 January.

Vaddady PK, Mehrotra N, Moore BM, Yates CR, and Meibohm B. Pharmacokinetics of a novel combination of ∆9-tetrahydrocannabinol and celecoxib in porcine model of hemorrhagic shock. Biopharm Drug Dispos 2010 Dec 23 (epub ahead of print).

Kosanam H, Ma F, Ramagiri S, Kimura Y, Gududuru V, Deng W, Tigyi G, Miller DD, and Yates CR. Development of an LC-MS/MS assay to determine plasma pharmacokinetics of the radioprotectant octadecenyl thiophosphate (OTP) in monkeys. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 15;878(26):2379-83. Epub 2010 Jul 18.

Zeng K, Thompson KE, Yates CR, and Miller DD. Synthesis and biological evaluation of quinic acid derivatives as anti-inflammatory agents. BMCL 19 (2009) 5458–5460.

Ramagiri S, Ma F, Kosanam H, Wang X-D, Patil R, Miller DD, Geisert EE, and Yates CR. Fast and sensitive liquid chromatography/electrospray mass spectrometry method to study ocular penetration of EDL-155, a novel antitumor agent for retinoblastoma in rats. J Mass Spec 2009 Jan 21. [Epub ahead of print]

26

R I C H A R D E . L E E , P H . D . FR-Adjunct Professor

Member, St. Jude Children’s Research Hospital

B.Sc. (Honors Class 1), Chemistry, University of Newcastle-upon-Tyne, UK, 1989

Ph.D. (Organic Chemistry), University of Newcastle-upon-Tyne, UK, 1993

Research Interest

The research focus of Dr Lee’s laboratory is the design and synthesis of new drugs targeting non-classical antibacterial drug targets using interdisciplinary approaches and the latest technologies. His research design includes drug target selection from pathogen genome analysis, high throughput screen development of these targets, rational and combinatorial drug design and their subsequent synthesis.

Selected Publications

Hurdle JG, O'Neill AJ, Chopra I, Lee RE. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9(1):62-75, 2011.

Hevener KE, Yun MK, Qi J, Kerr ID, Babaoglu K, Hurdle JG, Balakrishna K, White SW, Lee RE. Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase. J Med Chem 53(1):166-177, 2010.

Budha NR, Lee RB, Hurdle JG, Lee RE, Meibohm B. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb) Sep;89(5):378-85, 2009.

Mahrous EA, Lee RB, Lee RE. Lipid profiling using two-dimensional heteronuclear single quantum coherence NMR. Methods Mol Biol 579:89-102, 2009.

Sun D, Xu H, Wijerathna SR, Dealwis C, Lee RE. Structure-Based Design, Synthesis, and Evaluation of 2'-(2-Hydroxyethyl)-2'-deoxyadenosine and the 5'-Diphosphate Derivative as Ribonucleotide Reductase Inhibitors. Chem Med Chem 2009 Oct;4(10):1649-56, 2009.

Hurdle JG, Yendapally R, Sun D, Lee RE. Evaluation of analogs of reutericyclin as prospective candidates for the treatment of staphylococcal skin infections. Antimicrob Agents Chemother Jul 6, 2009. [Epub ahead of print] PMID: 19581456.

Zhao W, Hevener KE, White SW, Lee RE, Boyett JM. A Statistical Framework to Evaluate Virtual Screening. BMC Bioinformatics Jul 20;10:225, 2009.

Sun D, Scherman MS, Jones V, Hurdle JG, Woolhiser LK, Knudson SE, Lenaerts AJ, Slayden RA, McNeil MR, Lee RE. Discovery, Synthesis, and Biological Evaluation of Piperidinol analogs With Anti-tuberculosis Activity. Bioorg Med Chem May 15;17(10):3588-94, 2009.

Hevener K, Zhao W, Ball D, Babaoglu K, Qi J, White S, Lee RE. Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. J Chem Inf Mod 49 (2), 444–460, 2009.

Aubry S, Lee RE, Mahrous EA, Small PL, Beachboard D, Kishi Y. Synthesis and Structure of Mycolactone E Isolated from Frog Mycobacterium. Org Lett 10 (23), 5385–5388, 2008.

Grimes KD, Lu Y, Zhang Y-M, Luna VA, Hurdle JG, Carson EI, Qi J, Kudrimoti S, Rock CO, Lee RE. Novel Acylphosphate Mimics that Target PlsY, an Essential Acyltransferase in Gram-Positive Bacteria. ChemMedChem 3 :1936-45, 2008.

27

M A R Y V . R E L L I N G , P H A R M . D . FR-Adjunct Professor

Member, St. Jude Children’s Research Hospital

B.S. (Pharmacy), College of Pharmacy, University of Arizona, Tucson, 1982

Pharm.D., College of Pharmacy, University of Utah, Salt Lake City, 1985

Research Interest Her primary interests are in antineoplastic pharmacokinetics and

pharmacodynamics in children; pharmacogenetics of antileukemic therapy, and host- and treatment-related risk factors for adverse effects and secondary malignancies. Dr. Relling is one of the Principal Investigators within the Pharmacogenomics Research Network. The impetus for her research is the need to improve drug therapy of childhood leukemia by better understanding the contributions of and mechanisms underlying interindividual differences in pharmacokinetics and pharmacodynamics.

Selected Publications

Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Coustan-Smith E, Jeha S, Cheng C, Metzger ML, Bhojwani D, Inaba H, Raimondi SC, Onciu M, Howard SC, Leung W, Downing JR, Evans WE, Relling MV. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 29:386-91, 2011

Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (in press)

Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, Relling MV. Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (in press)

Panetta JC, Sparreboom A, Pui CH, Relling MV, Evans WE. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 6:e1001019, 2010.

Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol 11:507-9, 2010.

Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, Ar K, Wilson CS, Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Downing JR, Relling M, Yang J, Bhojwani D, Carroll WL, Camitta B, Reaman GH, Smith M, Hunger SP, Willman CL. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116:4874-84, 2010.

Pottier N, Paugh SW, Ding C, Pei D, Yang W, Das S, Cook EH, Pui CH, Relling MV, Cheok MH, Evans WE. Promoter Polymorphisms in the β-2 Adrenergic Receptor Are Associated With Drug-Induced Gene Expression Changes and Response in Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 88:854-61, 2010.

Chen SH, Pei D, Yang W, Cheng C, Jeha S, Cox NJ, Evans WE, Pui CH, Relling MV. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 88:191-6, 2010.

28

E R I N S C H U E T Z FR-Adjunct Associate Professor

Member, St. Jude Children’s Research Hospital

PhD - Medical College of Virginia, Richmond

Research Interest

Regulation of cytochrome P4503A Interplay of drug transport, cytochromes P450 and nuclear hormone receptors Pharmacogenetics of drug transporters, cytochromes P450 and nuclear hormone receptors

Selected Publications

Lin YS, Yasuda K, Assem M, Cline C, Barber J, Li CW, Kholodovych V, Ai N, Chen JD, Welsh WJ, Elkins S, Schuetz EG. The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos Jun;37(6):1295-304, 2009.

Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, Zhu J, Millstein J, Sieberts S, Lamb J, GuhaThakurta D, Derry J, Storey J, Mehrabian M, Drake TA, Lusis AJ, Smith RC, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich R. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 6(5):e107, 2008. PMCID: PMC2365981.

Poonkuzhali B, Lamba J, Strom S, Sparreboom A, Thummel K, Watkins P, Schuetz E. Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos 36:780-95, 2008.

Lamba J, Lamba V, Strom S, Venkataramanan, Schuetz E. Novel SNPs in the Promoter and Intron 1 of Human PXR/NR1I2 and Their Association with CYP3A4 Expression. Drug Metab Dispos 36:169-81, 2008.

Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. A Common Polymorphism in the Bile Acid Receptor FXR is Associated with Decreased Hepatic Target Gene Expression. Mol Endocrinol 21(8):1769-1780, 2007.

Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, Thummel KE. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116(6):1703-1712, 2006.

Finkelstein D, Lamba V, Assem M, Rengelshausen J, Yasuda K, Strom S, Schuetz E. The ADME transcriptome in Hispanic versus White donor livers: Evidence of a globally enhanced NR1I3 (CAR, Constitutive Androstane Receptor) gene signature in Hispanics. Xenobiotica 36:989-1012, 2006.

Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins P, Schuetz E. MDR1 genotype is associated with Hepatic CYP3A4 basal and induction phenotype. Clin Pharmacol Therap 79(4):325-338, 2006.

29

J O H N S C H U E T Z , P H . D . FR-Adjunct Professor

Member, St. Jude Children’s Research Hospital

B.A., University of Minnesota, Minneapolis, 1979

Ph.D., Medical College of Virginia, Richmond, 1984

Research Interest Our laboratory focuses on the function and regulation of mammalian ABC (ATP-binding cassette) transporters. These transporters play an critical role in drug penetration and retention in biological systems. We have recently defined the function of two new ABC transporters, MRP4 and BCRP. MRP4 is unique among ABC transporters in its ability to remove specific nucleotides from cells. This property allows cells that express high levels of it to evade chemotherapy by removing the nucleotide forms of nucleoside analogues. The other transporter is BCRP which is highly and uniquely expressed in mammalian stem cells. This unique

expression allows BCRP to protect stem cells from chemotherapeutic insults. Besides determining ABC-transporter function, we are evaluating the signals that lead to up or down regulation of these genes. The knowledge of function as well as regulation should facilitate the future design of more effective chemotherapeutic regimens. Selected Publications

Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KFK, Hrycyna CA, Schuetz JD. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67:6965-6972, 2007.

Li C, Krishnamurthy PC, Penmatsa H, Marrs KL, Wang XQ, Zaccolo M, Jalink K, Li M, Nelson DJ, Schuetz JD, Naren AP. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell 131(5):940-951, 2007.

Krishnamurthy P, Du G, Fukuda Y, Sun D, Mercer K, Wang J, Sosa-Pineda B, Murti G, Schuetz JD. Identification of a mitochondrial porphyrin transporter. Nature 443:586-589, 2006.

Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, Hagey L, Schuetz JD, Boyer JL. Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 43(5):1013-1021, 2006.

Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, Schuetz JD. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279:24218, 2004.

Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic Mrp4 and Sult2A as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 279:22250, 2004.

Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD. Mrp4 confers resistance to topotecan and acts as a double agent in protecting the brain from chemotherapy. Mol Cell Biol 24(17):7612-21, 2004.

Lamba JK, Adachi M, Sun D, Tammur J, Schuetz EG, Allikmets R, Schuetz JD. ABCC4 Gene Structure Reveals Phylogenetically Conserved Nonsense Exons that are Regulated by Nonsense Mediated mRNA Decay. Hum Mol Genet 12(2):99-109, 2003.

30

S C O T T E . S N Y D E R , P H . D .

FR-Adjunct Associate Professor Associate Member, St. Jude Children’s Research Hospital

BS. Virginia Polytechnic Institute and State University, Blacksburg, VA, 1986

PhD, Purdue University, West Lafayette, IN, 1993

Research Interest

Development of novel radiopharmaceuticals for positron emission tomographic (PET) imaging. Particular PET imaging applications include: Functional characterization of tumors; Therapy response monitoring; and Investigation of therapy-induced neurological disorders in cancer survivors.

Selected Publications

Li X, Jung Y-W, Snyder SE, Blair J, Sherman PS, Desmond T, Frey KA, Kilbourn MR. 5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: Potential new GABAA receptor radioligands. Nucl Med Biol, 35:549-59, 2008.

Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR. In vivo butyrylcholinesterase activity is not increased in Alzheimer synapses. Ann Neurol 59:13-20, 2006.

Shao X, Koeppe RA, Butch ER, Kilbourn MR, Snyder SE*. Evaluation of 18F-labeled acetylcholinesterase substrates as PET radiotracers. Bioorg Med Chem 13:869-875, 2005.

Shao X, Butch ER, Kilbourn MR, Snyder SE*. N-[18F]Fluoroethylpiperidinyl, N-[18F]fluoroethylpiperidinemethyl and N-[18F]fluoroethylpyrrolidinyl esters as radiotracers for acetylcholinesterase. Nucl Med Biol 30:491-500, 2003.

Shao X, Lisi JM, Butch ER, Kilbourn MR, Snyder SE*. N-Methylpiperidinemethyl, N-methylpyrrolidyl and N-methylpyrrolidinemethyl esters as PET radiotracers for acetylcholinesterase activity. Nucl Med Biol 30:293-302, 2003.

Koeppe RA, Raffel DM, Snyder SE, Ficaro EP, Kilbourn MR, Kuhl DE. Dual-[11C]tracer single-acquisition positron emission tomography studies. J Cereb Blood Flow Metab 21:1480-1492, 2001.

Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS. Acetylcholinesterase inhibition increases in vivo radioligand binding to muscarinic acetylcholine receptors. J Cereb Blood Flow Metab 21:144-148, 2001.

Snyder SE*, Gunupudi N, Sherman PS, Butch ER, Skaddan MB, Kilbourn MR, Koeppe RA, Kuhl DE. Radiolabeled cholinesterase substrates: In vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity. J Cereb Blood Flow Metab 21:132-143, 2001.

Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS, Desmond TJ, Frey KA. Synthesis, 18F-labeling and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors. J Med Chem 43:4552-4562, 2000.

31

C L I N T O N S T E W A R T , P H A R M . D . FR-Professor

Member, St. Jude Children’s Research Hospital

B. S. (Pharmacy), Auburn University, 1976

Pharm.D., University of Tennessee Center for the Health Sciences, Memphis, 1983

Research Interest My research interests focus on: Clinical pharmacokinetics, pharmacodynamics, and pharmacogenetics of anticancer drugs in children; Role of ABC transporters in CNS penetration of camptothecin analogs; Multidrug resistance proteins (e.g., MRP4, BCRP) in camptothecin pharmacology and physiology; Novel methods to optimize drug exposure in children with cancer (pharmacokinetically guided dosing); Use of preclinical models to enhance design of clinical trials of new agents in children with cancer; Role of pharmacokinetics in drug development in pediatric oncology; and Use of clinical pharmacology to optimize therapy for children with primary CNS malignancies

Selected Publications Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute

carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17(1):89-99, 2011.

Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM, Geyer JR. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol February 3, 2011.

Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium Study PBTC-018. J Clin Oncol December 13, 2010.

Nemeth KM, Federico S, Carcaboso AM, Shen Y, Schaiquevich P, Zhang J, Egorin M, Stewart C, Dyer MA. Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer September 3, 2010.

Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of Lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol August 16, 2010.

Bai F, Tagen M, Colotta C, Miller L, Fouladi M, Stewart CF. Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci July 30, 2010.

Beaty O, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 55(3):440-445, 2010.

Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol July 6, 2010.

32

T H O M A S R . W E B B , P H . D . FR-Adjunct Professor

Member, St. Jude Children’s Research Hospital

Ph.D., University of California, Santa Cruz

Research Interest Synthetic organic chemistry and medicinal chemistry:

Heterocyclic and enantioselective synthesis, synthesis of non-peptide peptide mimics, protein kinase inhibitor design and synthesis, synthesis of active small molecules based on the pharmacophores of natural products;

Lead discovery: integration of cheminformatics, small molecule library design and medicinal chemistry, synthesis of novel combinatorial templates

Selected Publications

Lagisetti C, Pourpak A, Goronga T, Jiang Q, Cui Xiaoli, Hyle J, Lahti J, Morris S, Webb T. Synthetic mRNA Splicing Modulator Compounds with In Vivo Anti-tumor Activity. J Med Chem 52:6979-6990, 2009.

Boyd VA, Mason J, Hanumesh P, Price J, Russell CJ, Webb TR. 2-Substituted-4,5-Dihydroxypyrimidine-6-Carboxamide Antiviral Targeted Libraries. J Comb Chem 11:1100-1104, 2009.

Kasinathan RS, Goronga T, Messerli SM, Webb TR, Greenberg RM. Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel. FASEB J [Epub ahead of print] Sept 2009.

Aragon AD, Imani RA, Blackburn VR, Cupit PM, Melman SD, Goronga T, Webb TR, Loker ES, Cunningham C. Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol 164:57-65, 2009.

Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SW. Anaplastic Lymphoma Kinsase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9(3):331-356, 2009.

Slavish PJ, Jiang Q, Cui X, Morris SW, Webb TR. Design and synthesis of a novel tyrosine kinase inhibitor template. Bioorg Med Chem 17(9):3308-3316, 2009. PMCID: PMC2696309

Lee JY, Im I, Webb TR, McGrath D, Song MR, Kim YC. Combinatorial synthesis and biological evaluation of peptide-binding GPCR-targeted library. Bioorg Chem 37(3):90-95, 2009.

Lagisetti C, Pourpak A, Jiang Q, Cui X, Goronga T, Morris SW, Webb TR. Antitumor Compounds Based on a Natural Product Consensus Pharmacophore: J Med Chem 51:6220-6224, 2008.

Webb TR, Venegas RE, Wang J, Deschenes A. Generation of New Synthetic Scaffolds Using Framework Libraries Selected and Refined via Medicinal Chemist Synthetic Expertise. J Chem Inf Mod 48 (4), 882-888, 2008.

Webb TR, McGrath D, Wang J, Li R, Jiang L, Sviridov S. Application of a Novel Design Paradigm to Generate General Nonpeptide Combinatorial Scaffolds Mimicking Beta Turns: Part II; Synthesis of Agonists of Melanocortin Receptors. J Comb Chem 9, 704-710, 2007.

Zhu T, Yan Z, Chucholowski A, Webb TR, Li R. Polymer-supported Synthesis of Pyridone-focused Libraries as Inhibitors of Anaplastic Lymphoma Kinase. J Comb Chem 8(3), 401, 2006.

33

J U N J . Y A N G , P H . D . Assistant Member, St. Jude Children’s Research Hospital

Ph.D., Purdue University (West Lafayette, IN), 2006

Research Interest

The research focus of my group is pharmacogenomics of treatment outcomes (e.g. relapse) of childhood acute lymphoblastic leukemia (ALL). The goals of our research are to elucidate biological pathways dictating response to antileukemic drugs, to identify genetic predictors for drug resistance which can be utilized for treatment individualization, and to develop novel therapeutic agents to overcome drug resistance. We have led the first genome-wide association study to identify germline genetic variations associated with minimal residual disease in response to remission induction therapy in children with ALL (JAMA 301:393) and the first genome-wide interrogation of copy number alterations related to ALL relapse (Blood 112:4178). We are particularly interested in the genetic basis for racial/ethnic differences in ALL treatment outcomes. Our group is part of the NIH

Pharmacogenomics Research Network (PGRN) and the Pharmacogenomic of Anticancer Agents Research in Children project (PAAR4Kids). Selected Publications

Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, Dunnenberger HM, Marsh S, McLeod HL, Giacomini K, Becker ML, Gaedigk R, Leeder JS, Kager L, Relling MV, Evans W, Klein TE, Altman RB. PharmGKB summary: methotrexate pathway. Pharmacogenetics and Genomics (in press) 2011.

Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui C-H, Evans WE, Relling MV. Ancestry and Pharmacogenomics of Relapse in Acute Lymphoblastic Leukemia. Nat Genet 43(3):237-241 (2011).

Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, Ar K, Wilson CS, Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Downing JR, Relling M, Yang JJ, Bhojwani D, Carroll WL, Camitta B, Reaman GH, Smith M, Hunger SP, Willman CL. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. [Epub ahead of print]PMID: 20699438 (2010).

Meeker ND, Yang JJ, Schiffman JD. Pharmacogenomics of pediatric acute lymphoblastic leukemia. Expert Opin Pharmacother. [Epub ahead of print] (2010).

Atkinson EJ, McDonnell SK, Witte JS, Crawford DC, Fan Y, Fridley B, Li D, Li L, Rodin A, Sadee W, Speed T, Weiss ST, Yang JJ, Yerges L, Schaid DJ. Lessons learned from the Fifth Statistical Analysis Workshop of the Pharmacogenetics Research Network. Pharmacogenomics (In press) (2011).

Yang W, Treviño LR, Yang JJ, Pui CH, Evans WE, Relling MV. ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia 24(4):894-896 (2010).

34

PROGRAMS OF STUDY

The Department of Pharmaceutical Sciences offers the Master of Science and Doctor of Philosophy degrees through the College of Graduate Health Sciences at The University Of Tennessee Health Sciences Center in Memphis. Areas of specialized studies are in medicinal chemistry and pharmaceutics. Medicinal chemistry includes the design, synthesis and evaluation of compounds with potential therapeutic applications. Pharmaceutics includes the development of novel dosage forms, biopharmaceutics, pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmaceutical technology. Normally, about four years are required for a well-prepared student to obtain the Ph.D. Graduates of the program in the Department of Pharmaceutical Sciences are prepared to assume positions of responsibility in academia, the pharmaceutical industry, government, and other health-related organizations and institutions. The nature and variety of research projects available to students reflect the stimulating and dynamic environment of the health science center and provide for truly meaningful research.

DUAL PHARM. D./PH.D. PROGRAM

UT College of Pharmacy offers an accelerated, integrated program, which combines study for the Doctor of Pharmacy (Pharm.D.) degree with the opportunity to earn the Ph.D. The program requires approximately seven years to complete, including summer research. This innovative dual degree program is designed to reduce the total time needed for completion while maintaining the high standards for both programs individually. Additional information about the dual degree program may be obtained by contacting Dr. C. Ryan Yates (cyates4@uthsc.edu).

COST OF STUDY/FINANCIAL AID

Tuition and fees for Tennessee residents are $4,338 per semester and $11,883 per semester for non-residents. A limited number of predoctoral fellowships are available on a competitive basis to qualified applicants. These provide an annual stipend of $23,000 plus a waiver of tuition. APPLICATIONS

The normal admission time for new students is in the fall semester, which usually begins in mid-August. Prospective students should submit a completed application form and supporting documents no later than March 15 for admission in the fall semester. Generally a minimum undergraduate grade point average of 3.0 on a 4.0 scale is required. All applicants are required to take the Graduate Record Examination (GRE) and achieve a minimum combined score (verbal and quantitative) of 1,000 (or a combined minimum score of 300 (150 on verbal and 150 on quantitative) on the new GRE score scale) and a minimum score of 3.5 on the analytical section. Foreign applicants whose native language is not English are required to take the Test of English as Foreign Language (TOEFL) and achieve a minimum score of 213 on the computer-based test or 79 on the internet-based test. It is also recommended that the Test of Spoken English (TSE) be taken. Applications are accepted from students with a B.S. or M.S. degree in pharmacy, chemistry, biology, mathematics, engineering or other appropriate disciplines.

You may apply on-line at http://www.uthsc.edu/admiss/Application.html. Look under College of Graduate Health Science to select our program. On-line applicants are not required to pay the $75.00 application fees.

35

Note that there are no separate forms to apply for financial assistance. Successful applicants will be automatically considered for financial assistance. Arrange for recommendation letters (at least two), official transcripts of all your college level academic work, GRE scores, and TOEFL scores (if English is not your first language) to be sent to the following address:

ATTN: Admissions Counselor Office of Enrollment Services University of Tennessee Health Science Center 910 Madison Avenue, Suite 525 Memphis, TN 38163. EVERY IMPORTANT. NON-US ALLICANTS, PLEASE NOTE: Official test scores and three letters of recommendation must be sent directly from the contributing source and not by the student to the address listed above (i.e., ATTN: Admissions Counselor etc). Applicants may initiate the application process with uncertified transcripts. However, we require that transcripts from any non-US institution must be verified and certified to generate a Grade Point Average (GPA) before an official letter of admission will be sent to the applicant. Service agencies include but are not limited to Educational Credit Evaluation (ECE) eval@ece.org, World Education Services (WES) support@wes.org, Association of Collegiate Registrars and Admission Officers (AACRAO) oies@aacrao.org. These agencies and others charge a fee for services. Document by document certification is not adequate. CONTACT

For more information, please contact Dr. Isaac O. Donkor Director of Graduate Programs Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee 847 Monroe Avenue, Suite 327E Memphis, Tennessee 38163 Telephone: (901) 448-7736 FAX: (901) 448-6828 Email: idonkor@uthsc.edu

36

OUR HOMETOWN, MEMPHIS_______________________________ The fourteenth largest city in the nation, Memphis is many different things to many different people: the world capitol of barbeque pork to the discriminating gourmet. home of the blues and Beale Street to the music aficionado; birthplace of rock-and-roll and site of Elvis Presley’s Graceland mansion to the rock-o-phile, host of the world’s art treasures through Wonders Series, the Memphis International Cultural Series to the connoisseur; site of the world’s largest cotton market to the historical scholar; home of the National Civil Rights Museum. For the sports enthusiast, Memphis is home to the NBA Grizzlies and the Triple A baseball Red Birds team. Lastly, but certainly not least Memphis is the home of the largest medical center in the Southeast.

Whatever you and your family are looking for, chances are you’ll find it in Memphis. The city holds many surprises for the unknowing; serene botanic gardens in the heart of the city; victorian architecture and stately homes amid the bustle of downtown; wineries, world-class sporting facilities, outdoor activities, a new downtown trolley line, and much, much more.

Memphis’s central geographic location provides easy access. The city is the headquarters of Federal Express and is one of three national hubs for Northwest Airlines. Memphis International Airport is the largest cargo airport in the world and is also served by Delta, American, United and USAir.

Memphis is located in extreme southwest Tennessee with the Mississippi River at its doorstep. Mississippi and Arkansas are adjacent neighbors. The city is at the junction of interstate highways 55 and 40, with I-240 providing circumferential transportation routes around the city.

The University Of Tennessee, Health Science Center, is located within blocks of downtown, with easy access to I-240 and only minutes from Memphis International Airport. The 55-acre UTHSC campus is the hub of the Memphis Medical Center. To learn more about Memphis click on this link: http://www.cityofmemphis.org